Immunovant reports GAAP loss of $0.47 per share, beating estimates by $0.27

Summary

Immunovant posted GAAP earnings per share of -$0.47, beating expectations by $0.27, according to a Seeking Alpha headline published November 9, 2026. The source item carried only a headline, so it gives no reporting period, revenue figures, or the estimates used for the comparison.

Timeline

1. Seeking Alpha

   9 Nov 2026, 12:20 UTCSource ↗

   Seeking Alpha reports that Immunovant's GAAP EPS of -$0.47 beat by $0.27.